story of the week
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
N. Engl. J. Med 2024 Jan 25;390(4)301-313, P Sonneveld, MA Dimopoulos, M Boccadoro, H Quach, PJ Ho, M Beksac, C Hulin, E Antonioli, X Leleu, S Mangiacavalli, A Perrot, M Cavo, A Belotti, A Broijl, F Gay, R Mina, IS Nijhof, NWCJ van de Donk, E Katodritou, F Schjesvold, A Sureda Balari, L Rosiñol, M Delforge, W Roeloffzen, T Silzle, A Vangsted, H Einsele, A Spencer, R Hajek, A Jurczyszyn, S Lonergan, T Ahmadi, Y Liu, J Wang, D Vieyra, EMJ van Brummelen, V Vanquickelberghe, A Sitthi-Amorn, CJ de Boer, R Carson, P Rodriguez-Otero, J Bladé, P MoreauFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.